Third Quarter 2026 Earnings Call - MIRION TECHNOLOGIES INC

Financial Performance:

• Q3 2026 total revenue reached $278 million, a 24.5% year-over-year increase, driven by 6.5% organic growth and M&A contributions.
• Adjusted EBITDA grew 23.7% YoY to $65 million, with margins at 23.3% (a contraction from 23.5% last year due to nuclear/safety headwinds and M&A, offset by a 200 bps expansion in Medical).
• Adjusted Free Cash Flow for the quarter was $47 million, bringing year-to-date FCF to $107 million, representing a 58% conversion of adjusted EBITDA.
• Net leverage stood at 3.1x (2.8x excluding recent share repurchases) and is expected to improve to approximately 2.6x by year-end.
• Effective debt costs remain low with an average coupon below 3%, providing a significant advantage over straight debt.
• The company completed a $100 million share repurchase program and announced a new $250 million buyback, with $235 million remaining; $56 million was repurchased in Q3.

Guidance and Future Outlook:

• Revised full-year 2026 revenue guidance raised to $11.5–$11.6 billion (previously $11.0–$11.3 billion) with organic growth expected to be 7–8%.
• Q4 2026 is projected to see mid-to-high teens organic revenue growth, with Nuclear and Safety expected to grow high teens and Medical mid-single digits.
• Full-year adjusted EBITDA guidance adjusted to $285–$292 million (margins 24.7–25.2%), reflecting Q3 headwinds but implying margin expansion in Q4.
• Adjusted EPS guidance tightened to $0.50–$0.54 per share; free cash flow guidance raised to $170–$185 million.
• Management dropped the specific 2028 30% EBITDA margin target as "too aggressive," prioritizing strategic AI/cyber investments and Paragon integration over near-term margin extraction.
• Long-term outlook emphasizes a multi-decade capital growth cycle driven by nuclear fleet upgrades, life extensions, and SMR development.

Business Segments and Product Lines:

• Nuclear and Safety: Q3 revenue grew 34% (organic +6.3%); nuclear power organic revenue surged 14% driven by installed base and SMRs. Paragon integration continues with 12% growth in Q3.
• Medical: Q3 revenue grew 6.7% (organic +6.6%); margins expanded 200 bps to 37.8% driven by RTQA and operating leverage, though growth was slightly below expectations due to one-time quality costs.
• Order Book: Total orders excluding M&A grew 62% to $340 million; nuclear power orders jumped 105%. Total orders including M&A reached $386 million.
• Backlog: Total backlog stands at $1.25 billion, up significantly from $816 million last year, with high visibility into 2027 revenue recognition.
• New Products/Agreements: Secured $140 million in large opportunity wins in Q3; awarded new US DOE and Egyptian large-scale new build orders; strategic partnership with EDF for French new builds (awaiting funding).
• SMR Market: Booked $16 million in SMR orders; positioned across 11 different SMR designers with a dominant footprint in instrumentation and services.

Market and Competitive Landscape:

• Nuclear Market: Driven by three "waves": catch-up capital spending (U.S. fleet spending reached $9.7/MWh in 2025), life extensions (96% of U.S. reactors approved for 20-year extension), and digital transformation.
• Demand Drivers: Global electrical capacity deficit and data center growth are accelerating multi-year utility commitments to extend and upgrade existing fleets.
• Competitive Position: Mirion holds presence in >98% of global nuclear reactors; strong positioning in SMR sector with "premium" pricing power and deep partnerships with major developers.
• Medical: Outperforming sector-wide competitors despite a two-year flat spot in the broader medical environment; recovery seen in OEM and nuclear medicine sectors.

Risks and Challenges:

• Margin Pressure: Short-term margin contraction in Nuclear and Safety due to Paragon legacy contract dilution, one-time adjustments, and AI investment front-loading.
• AI/Cyber Spending: Significant upfront OPEX and CAPEX required for AI infrastructure and cybersecurity, currently exceeding initial budgets by year-to-date, impacting near-term profitability.
• Regulatory/Economic Dependencies: European new build orders (EDF) pending EU funding approval; potential delays in SMR project timelines despite acceleration trends; inflationary pressure on input costs (mitigated by escalation clauses).
• Medical Externalities: Macro factors and product-specific quality costs have tempered organic growth expectations in the medical segment.

Management Commentary and Tone:

• Tone: Highly confident and optimistic regarding nuclear tailwinds, describing the current environment as a "generational opportunity." Management expressed caution on immediate margin targets but reinforced long-term margin expansion potential.
• Strategic Pivot: CEO Tom Logan emphasized a shift from rigid near-term margin targets to investing heavily in AI and cybersecurity to capture long-term value, stating previous targets were becoming a distraction.
• Execution: Management highlighted strong execution in backlog conversion, noting 95% revenue visibility for the full year.

Analyst Questions and Answers:

• Nuclear Margins: Management clarified that underlying margins are healthy but currently suppressed by Paragon integration and AI spend; expects margin trajectory to moderate headwinds and return to expansion in 2027.
• AI Investment: Detailed AI spend ($4M+ YTD, projected >$5M full year) is allocated to data infrastructure, internal productivity, and customer-facing product development; breakeven timeline not yet set.
• Capital Allocation: Adopted a "20/40/40" model: 20% Capex/Org Growth, 40% M&A (bolt-on), 40% Shareholder returns (repurchases); prioritizing deleveraging to <3.0x by year-end.
• Large Orders: Q4 outlook includes ~$125M in potential new awards, including $80M from EDF projects pending EU funding.
• Inflation: Company is effectively managing inflation via procurement programs and escalation clauses in new large contracts; cost pressure is manageable.
• SMR Dynamics: Sector is accelerating, not slowing, with a focus on capital availability; Mirion maintains a premium pricing position as a trusted partner.

Other Key Points:

• Stock-Based Compensation: Beginning in 2026, stock-based compensation is included in the adjusted EPS calculation.
• Currency Impact: A weaker Euro in Q4 is expected to provide a slight tailwind; guidance assumes an exchange rate of 1.12 EUR/USD for Q4.
• Order Quality: Q3 orders included significant multi-year projects (DOE, EDF) alongside shorter-cycle installs, with a mix expected to convert revenue rapidly in 2026 and 2027.
• Cybersecurity: Highlighted as a critical component of AI spending due to exploding risks from frontier AI models.